90 related articles for article (PubMed ID: 10026853)
1. Tissue inhibitor of metalloproteinase expression. A target for gene therapy in renal cell carcinoma.
McElligott AM; Baker AH; McGlynn H
Adv Exp Med Biol; 1998; 451():73-7. PubMed ID: 10026853
[No Abstract] [Full Text] [Related]
2. High level expression of tissue inhibitors of metalloproteinases-1,-2 and -3 in melanoma cells achieved by adenovirus mediated gene transfer.
Ahonen M; Baker AH; Kähäri VM
Adv Exp Med Biol; 1998; 451():69-72. PubMed ID: 10026852
[No Abstract] [Full Text] [Related]
3. Rac affects invasion of human renal cell carcinomas by up-regulating tissue inhibitor of metalloproteinases (TIMP)-1 and TIMP-2 expression.
Engers R; Springer E; Michiels F; Collard JG; Gabbert HE
J Biol Chem; 2001 Nov; 276(45):41889-97. PubMed ID: 11551917
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells.
Ahonen M; Baker AH; Kähäri VM
Cancer Res; 1998 Jun; 58(11):2310-5. PubMed ID: 9622064
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-mediated expression of TIMP-1 and TIMP-2 in bone inhibits osteolytic degradation by human prostate cancer.
Deng X; He G; Levine A; Cao Y; Mullins C
Int J Cancer; 2008 Jan; 122(1):209-18. PubMed ID: 17847032
[TBL] [Abstract][Full Text] [Related]
6. Anti-invasive effect of MMI-166, a new selective matrix metalloproteinase inhibitor, in cervical carcinoma cell lines.
Iwasaki M; Nishikawa A; Fujimoto T; Akutagawa N; Manase K; Endo T; Yoshida K; Maekawa R; Yoshioka T; Kudo R
Gynecol Oncol; 2002 Apr; 85(1):103-7. PubMed ID: 11925127
[TBL] [Abstract][Full Text] [Related]
7. The balance between MMP-2/-9 and TIMP-1/-2 is shifted towards MMP in renal cell carcinomas and can be further disturbed by hydrogen peroxide.
Hemmerlein B; Johanns U; Halbfass J; Böttcher T; Heuser M; Radzun HJ; Thelen P
Int J Oncol; 2004 May; 24(5):1069-76. PubMed ID: 15067327
[TBL] [Abstract][Full Text] [Related]
8. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
[TBL] [Abstract][Full Text] [Related]
9. Relative expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in mouse renal cell carcinoma cells regulates their metastatic potential.
Miyake H; Hara I; Gohji K; Yamanaka K; Hara S; Arakawa S; Nakajima M; Kamidono S
Clin Cancer Res; 1999 Oct; 5(10):2824-9. PubMed ID: 10537348
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma.
Kallakury BV; Karikehalli S; Haholu A; Sheehan CE; Azumi N; Ross JS
Clin Cancer Res; 2001 Oct; 7(10):3113-9. PubMed ID: 11595703
[TBL] [Abstract][Full Text] [Related]
11. Cell surface engineering of renal cell carcinoma with glycosylphosphatidylinositol-anchored TIMP-1 blocks TGF- β 1 activation and reduces regulatory ID gene expression.
Notohamiprodjo S; Djafarzadeh R; Rieth N; Hofstetter M; Jaeckel C; Nelson PJ
Biol Chem; 2012 Dec; 393(12):1463-70. PubMed ID: 23667903
[TBL] [Abstract][Full Text] [Related]
12. [Problems in the therapy of kidney neoplasms].
Masuda F
Nihon Hinyokika Gakkai Zasshi; 1985 Nov; 76(11):1612-8. PubMed ID: 3835352
[No Abstract] [Full Text] [Related]
13. miRNA-221 promotes proliferation, migration and invasion by targeting TIMP2 in renal cell carcinoma.
Lu GJ; Dong YQ; Zhang QM; Di WY; Jiao LY; Gao QZ; Zhang CG
Int J Clin Exp Pathol; 2015; 8(5):5224-9. PubMed ID: 26191221
[TBL] [Abstract][Full Text] [Related]
14. The potential of virus-based gene therapies for treatment of metastatic kidney cancer.
Dent P; Curiel DT; Fisher PB
Expert Rev Anticancer Ther; 2011 Jun; 11(6):809-11. PubMed ID: 21707273
[No Abstract] [Full Text] [Related]
15. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential.
Nishikawa A; Iwasaki M; Akutagawa N; Manase K; Yamashita S; Endo T; Kudo R
Gynecol Oncol; 2000 Nov; 79(2):256-63. PubMed ID: 11063654
[TBL] [Abstract][Full Text] [Related]
16. Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas.
Siddique K; Yanamandra N; Gujrati M; Dinh D; Rao JS; Olivero W
Int J Oncol; 2003 Feb; 22(2):289-94. PubMed ID: 12527924
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of immunization with interleukin-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma.
Hum Gene Ther; 1992 Dec; 3(6):691-703. PubMed ID: 1482709
[No Abstract] [Full Text] [Related]
18. Expression of matrix metalloproteinase (MMP) and tissue inhibitor of MMP (TIMP) genes in blasts of infant acute lymphoblastic leukemia with organ involvement.
Suminoe A; Matsuzaki A; Hattori H; Koga Y; Ishii E; Hara T
Leuk Res; 2007 Oct; 31(10):1437-40. PubMed ID: 17350093
[TBL] [Abstract][Full Text] [Related]
19. Microencapsulation of recombinant adenovirus within poly-DL-lactide-poly(ethylene glycol) microspheres for enhanced gene transfection efficiency and inhibitory effects on hepatocellular carcinoma cells in vitro.
Xia D; Feng LB; Wu XL; Xia GD; Xu L
Mol Med Rep; 2015 Aug; 12(2):2336-42. PubMed ID: 25845395
[TBL] [Abstract][Full Text] [Related]
20. Suppression of tumorigenicity and metastasis of human renal carcinoma cells by infection with retroviral vectors harboring the murine inducible nitric oxide synthase gene.
Juang SH; Xie K; Xu L; Shi Q; Wang Y; Yoneda J; Fidler IJ
Hum Gene Ther; 1998 Apr; 9(6):845-54. PubMed ID: 9581907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
